The researchers used the method, which is based on the Pup bacterial protein, to identify interaction partners of the T cell membrane receptor CD28.
The company said the funds will be used to expand its management team and complete commercialization of its mass spec multinozzle emitter array technology.
The company, which has just changed its name from Sygnis, has now completed the integration of several recent acquisitions including TGR Biosciences.
The platform can now measure RNA and proteins simultaneously at the single-cell level and can multiplex more than 100 proteins per experiment, the company said.
The company has developed a DNA barcode-based screening system that it said brings development time of its PCC affinity reagents down to around two weeks.
Fluidigm reported that its mass cytometry revenues jumped 32 percent while genomics revenues fell 5 percent year over year.
The company reported revenues of $443.7 million and organic growth of 3 percent, driven in large part by strength in its scientific instruments business.
Led by researchers at the University of Iceland, the study combined deep proteomic, genomic, and phenotypic data from a cohort of more than 5,000 subjects.
Waters said the acquisition is part of a strategy to develop simpler, more streamlined mass spec workflows that will be accessible to non-expert users.
The company posted Q2 revenues of $596.2 million, up from $558.3 million in Q2 2017, short of the average Wall Street estimate of $598 million.
As part of the deal, Waters has also placed a Synapt G2-Si mass spec instrument at Purdue University to help advance research applications for DESI.
According to Myriad, a similar deal is in the works with the pharmacy benefit management services provider for its GeneSight pharmacogenetic test.
The company said it plans to use the technology to derive clinical insights from the large-scale proteomic datasets generated by its SomaScan platform.
A Harvard Medical School-led team applied their SNP-seq and FREP approach to identify nearly 150 candidate functional SNPs for juvenile idiopathic arthritis.
JPK provides microscopy instrumentation for biomolecular and cellular imaging, as well as force measurements on single molecules, cells, and tissues.
The study, which coupled FAIMS to an Orbitrap mass spec, indicates the technology could streamline proteomics experiments without sacrificing depth of analysis.
An analysis of stomach and gastrointestinal samples suggests the Iceman munched on a high-fat diet of ibex, red deer, and einkorn plants before his final hike.
Researchers have found that the Btk-inhibitor ibrutinib, which is currently used to treat cancers that include types of lymphoma, could be effective in leukemia.
The firm, which specializes in multiplexed protein analysis, has placed CODEX systems in 10 sites and is planning a broad launch of the platform later this year.
Researchers affiliated with the Pancreatic Cancer Action Network found that treatment based on patient molecular profiles improved progression-free survival.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.